×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACRV – acrivon therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACRV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/7
04:05 pm
acrv
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
Low
Report
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
3/28
08:13 pm
acrv
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
High
Report
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
3/27
05:44 pm
acrv
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
High
Report
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
3/26
10:27 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/26
08:19 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at HC Wainwright from $22.00 to $19.00. They now have a "buy" rating on the stock.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at HC Wainwright from $22.00 to $19.00. They now have a "buy" rating on the stock.
3/19
08:00 am
acrv
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
Medium
Report
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
2/5
09:07 am
acrv
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer [Seeking Alpha]
High
Report
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer [Seeking Alpha]
2/5
08:00 am
acrv
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
High
Report
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
Date
Time
Symbol
Company Name
Action
%Chg
3/27/2025
05:44 pm
acrv
acrivon therapeutics, inc.
BEAT
Report
-10.4%
acrivon therapeutics, inc.
11/13/2024
07:00 am
acrv
acrivon therapeutics, inc.
MISS
Report
-6.4%
acrivon therapeutics, inc.
8/13/2024
08:00 am
acrv
acrivon therapeutics, inc.
BEAT
Report
-4.5%
acrivon therapeutics, inc.
5/14/2024
07:31 am
acrv
acrivon therapeutics, inc.
BEAT
Report
-1.4%
acrivon therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/7
04:05 pm
acrv
Form 8-K Acrivon Therapeutics, For: Apr 07
Low
Report
Form 8-K Acrivon Therapeutics, For: Apr 07
4/3
04:33 pm
acrv
Form 4 Acrivon Therapeutics, For: Apr 01 Filed by: Miller Mary
Medium
Report
Form 4 Acrivon Therapeutics, For: Apr 01 Filed by: Miller Mary
4/3
04:31 pm
acrv
Form 4 Acrivon Therapeutics, For: Apr 01 Filed by: Levy Adam D.
Medium
Report
Form 4 Acrivon Therapeutics, For: Apr 01 Filed by: Levy Adam D.
4/3
04:29 pm
acrv
Form 3 Acrivon Therapeutics, For: Apr 01 Filed by: Levy Adam D.
Medium
Report
Form 3 Acrivon Therapeutics, For: Apr 01 Filed by: Levy Adam D.
3/27
04:48 pm
acrv
Form 8-K Acrivon Therapeutics, For: Mar 27
High
Report
Form 8-K Acrivon Therapeutics, For: Mar 27
3/27
04:08 pm
acrv
Form 10-K Acrivon Therapeutics, For: Dec 31
High
Report
Form 10-K Acrivon Therapeutics, For: Dec 31
3/25
05:16 pm
acrv
Form 8-K Acrivon Therapeutics, For: Mar 25
High
Report
Form 8-K Acrivon Therapeutics, For: Mar 25
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: